| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;100:2541.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium (N.N., I.V., D.C.), and the Department of Physiology, Hamamatsu University School of Medicine, Japan (N.N.).
Correspondence to Désiré Collen, MD, PhD, Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Campus Gasthuisberg, B-3000 Leuven, Belgium. E-mail desire.collen{at}med.kuleuven.ac.be
BackgroundThe effects of alteplase (rtPA), streptokinase, and staphylokinase (rSak) on focal cerebral ischemia (FCI) and on pulmonary clot lysis (PCL) were studied in hamsters.
Methods and ResultsFCI was produced by ligation of the left
middle cerebral artery (MCA) and common carotid artery (CCA) and a
10-minute occlusion of the right CCA. FCI was measured after 24 hours
by 2,3,5-triphenyltetrazolium chloride
staining. 125I-fibrinlabeled plasma clots were injected
via the jugular vein, and clot lysis was determined from residual
radioactivity at 90 minutes. Study drugs were given
intravenously over 60 minutes. FCI increased from 1.2 (0.27
to 2.3) mm3 (median and 17th to 83rd percentile range,
n=24) in controls to 19 to 27 mm3 with
thrombolytic agent, with maximal rates at 0.13±0.05
mg/kg rtPA, 0.23±0.09 mg/kg streptokinase, and 0.037±0.025 mg/kg
rSak. PCL increased from 18±2% (mean±SEM, n=27) in controls to
85% with thrombolytics, with maximal rates at
0.12±0.03 mg/kg rtPA, 0.17±0.05 mg/kg streptokinase, and 0.018±0.002
mg/kg rSak. All agents caused maximal FCI and PCL rates at similar
doses without
2-antiplasmin and fibrinogen depletion.
Injection of 6 mg/kg human plasminogen combined with
streptokinase caused a "systemic fibrinolytic state" with
fibrinogen depletion. Maximal rates of FCI were obtained with
0.097±0.077 mg/kg streptokinase (P=0.26 versus
streptokinase alone) and of PCL with 0.010±0.002 mg/kg
(P=0.006 versus streptokinase alone).
ConclusionsThrombolytic agents cause similar dose-related extension of FCI after MCA ligation and PCL, irrespective of the agent or systemic plasmin generation.
Key Words: cerebral infarction plasminogen activators streptokinase stroke thrombolysis
This article has been cited by other articles:
![]() |
T.-T. Hong, J. Huang, and B. R. Lucchesi Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeprase Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H959 - H967. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Suzuki, F. Chen, Y. Ni, G. Marchal, D. Collen, and N. Nagai Microplasmin Reduces Ischemic Brain Damage and Improves Neurological Function in a Rat Stroke Model Monitored With MRI Stroke, October 1, 2004; 35(10): 2402 - 2406. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. F. Hamann, D. Burggraf, H. K. Martens, M. Liebetrau, G. Jager, N. Wunderlich, M. DeGeorgia, and D. W. Krieger Mild to Moderate Hypothermia Prevents Microvascular Basal Lamina Antigen Loss in Experimental Focal Cerebral Ischemia Stroke, March 1, 2004; 35(3): 764 - 769. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Nagai, M. De Mol, B. Van Hoef, M. Verstreken, and D. Collen Depletion of circulating {alpha}2-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization Blood, May 15, 2001; 97(10): 3086 - 3092. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |